Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 20/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4217787 | 0.93 | CETP (0.38) | CETP | |
| SCHEMBL4223082 | 0.92 | CETP (0.38) | CETP | |
| SCHEMBL13779222 | 0.91 | CETP (0.39) | CETP | |
| SCHEMBL4179456 | 0.91 | CETP (0.38) | CETP | |
| SCHEMBL13779225 | 0.90 | CETP (0.37) | CETP | |
| SCHEMBL3906593 | 0.90 | CETP (0.37) | CETP | |
| SCHEMBL3906578 | 0.90 | CETP (0.37) | CETP | |
| SCHEMBL3913678 | 0.89 | CETP (0.41) | CETP | |
| SCHEMBL13779229 | 0.89 | CETP (0.36) | CETP | |
| SCHEMBL3916157 | 0.88 | CETP (0.36) | CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090181929-A1 | ORGANIC COMPOUNDS | KONISHI KAZUHIDE | 2009-07-16 | — | — | US | disclosed |
| US-20090181929-A1 | ORGANIC COMPOUNDS | KONISHI KAZUHIDE | 2009-07-16 | — | — | US | disclosed |
| US-20090181929-A1 | ORGANIC COMPOUNDS | KONISHI KAZUHIDE | 2009-07-16 | — | — | US | disclosed |
| EP-2018376-A1 | BENZYLAMINE DERIVATIVES AS CETP INHIBITORS | Novartis Pharma AG (CH) | 2009-01-28 | — | — | EP | disclosed |
| WO-2007132906-A1 | BENZYLAMINE DERIVATIVES AS CETP INHIBITORS | NOVARTIS AG (CH) | 2007-11-22 | — | — | WO | disclosed |
| WO-2007132906-A1 | BENZYLAMINE DERIVATIVES AS CETP INHIBITORS | NOVARTIS AG (CH) | 2007-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181929-A1 | ORGANIC COMPOUNDS | CETP, NPC1, LCAT | CETP 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.